US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Congenital Adrenal Hyperplasia · Polycystic Ovary Syndrome · SPRB
SPRUCE BIOSCIENCES
SPRUCE BIOSCIENCES, INC.
SPRUCE BIOSCIENCES drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2016 Founded
27 Employees
Public company Type
SPRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 27
- Programs
- 5
- Drugs
- 3
- Patents
- 9
SPRUCE BIOSCIENCES pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SPRUCE BIOSCIENCES drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to SPRUCE BIOSCIENCES in public FDA and regional records.